Animal and laboratory studies have previously shown that blue light may be a factor in the pathogenesis of AMD, but results in the few studies, the association between sun exposure and AMD in human populations examined inconsistent. Little attention has been paid to the possible interactions between antioxidants and exposure, although it is believed that the negative effects of sunlight by the protective effects of antioxidants can alleviate werden check information here here .753 participants aged 65 and over were selected randomly in seven centers, Bergen in Norway, Tallinn in Estonia, Belfast in the UK, Paris-Creteil in France, Verona in Italy, Thessaloniki in Greece and Alicante in Spain. The average age of participants was 73, For each period were women. Blue light exposures tended to be higher in participants from centers in southern Europe, while the in an in an exclusively urban center had the lowest exposures.

Forward-Looking StatementsAll statements in this press release that are not historical facts, are forward-looking statements , which under the provisions of the Private Securities Litigation Reform Act of 1995. May be forward – looking statements are identified by the words ‘project,”believe,”expect,”plan,”expect,”estimate,”intend,”should,”would,”may,”will ”could that ‘or other similar expressions and include statements regarding the safety and efficacy of RGN-137, RGN-259, RGN-352, RGN-457 and the status and prospects of all ongoing preclinical studies related to RGN-457. March 2008, and from those stated or implied by such forward-looking statements because the Company does not prove the product candidates, the safety and / or efficacy in current or future clinical trials or as a result of various important factors in the Company’s filings with the described with the described Securities and Exchange Commission , including those in the ‘Risk Factors’in our Annual Report on Form 10-K for the year ended In December 2007 with the SEC on 28 March 2008, and other periodic reports filed with the SEC identified. All forward-looking statements in this press release reflect the views of the Company only as of the date should not be should not be considered as representing its views invoked at a later time. The Company anticipates that subsequent events and developments may cause its views to change this, and the Company specifically disclaims any obligation to update this information future events or otherwise, required by law.

Among the highlights his presentation, Dr. Zeuzem reports: – Combining ITMN-191 plus the standard of care to 14 days led to rapid and sustained reductions of HCV RNA. Noted Substantial antiviral activity of the q8h and q12h doses cohort which came the fastest fall in HCV RNA in ITMN-191 900 mg of once every 12 hours doses cohort of. 180 000 USD reaches deal to discrimination on charge of Spanish-speaking people Settle.